1. A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY. (12th June 2019) Authors: Mato, A.R.; Schuster, S.J.; Lamanna, N.; Pagel, J.M.; Flinn, I.W.; Barrientos, J.; Reeves, J.A.; Cheson, B.D.; Barr, P.M.; Kambhampati, S.; Lansigan, F.; Pu, J.J.; Skarbnik, A.; Fonseca, G.; Dorsey, C.; LaRatta, N.M.; Weissbrot, H.; Svoboda, J.; Luning Prak, E.T.; Tsao, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AN IMPROVED BENEFIT‐RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES. (12th June 2019) Authors: Flinn, I.W.; Davids, M.S.; Hillmen, P.; Montillo, M.; Delgado, J.; Kuss, B.J.; Tam, C.S.; Jäger, U.; Ghia, P.; Stilgenbauer, S.; Lustgarten, S.; Weaver, D.T.; Youssoufian, H.; Cymbalista, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AN ONGOING PHASE 2 STUDY OF IBRUTINIB COMBINED WITH VENETOCLAX IN PATIENTS WITH TREATMENT‐NAÏVE CLL/SLL. (June 2017) Authors: Ghia, P.; Tam, C.S.; Siddiqi, T.; Stevens, D.; Flinn, I.W.; Russell, K.; Eckert, K.; Zhou, C.; Ninomoto, J.; James, D.F.; Wierda, W.G. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 428 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL. (12th June 2019) Authors: Ghia, P.; Flinn, I.W.; Lamanna, N.; Montillo, M.; Illés, Á.; Etienne, G.; Delgado, J.; Kuss, B.J.; Tam, C.S.; Offner, F.; Bosch, F.; Davids, M.S.; Jäger, U.; Cymbalista, F.; Weaver, D.T.; Lustgarten, S.; Youssoufian, H.; Stilgenbauer, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. HEALTH‐RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2) VERSUS R PLUS PLACEBO. (12th June 2019) Authors: Leonard, J.P.; Trněny, M.; Izutsu, K.; Fowler, N.H.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.M.; Scheinberg, P.; Flinn, I.W.; Moreira, C.; Tabah, A.; Abouzaid, S.; Kalambakas, S.; Fustier, P.; Wu, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 232 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. IBRUTINIB DECREASES OBINUTUZUMAB‐INDUCED SECRETION OF CYTOKINES ASSOCIATED WITH INFUSION‐RELATED REACTIONS IN PATIENTS WITH CLL: ANALYSIS FROM THE ILLUMINATE STUDY. (12th June 2019) Authors: Greil, R.; Tedeschi, A.; Moreno, C.; Anz, B.; Larratt, L.; Simkovic, M.; Gill, D.; Gribben, J.G.; Flinn, I.W.; Wang, Z.; Cheung, L.W.; Nguyen, A.N.; Zhou, C.; Styles, L.; Demirkan, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R‐CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY. (12th June 2019) Authors: Morschhauser, F.; Flinn, I.W.; Gasiorowski, R.; Illés, Á.; Feugier, P.; Greil, R.; Johnson, N.A.; Larouche, J.; Lugtenburg, P.J.; Patti, C.; Salles, G.; Trněný, M.; de Vos, S.; Mir, F.; Kornacker, M.; Punnoose, E.A.; Samineni, D.; Szafer‐Glusman, E.; Petrich, A.; Sinha, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB VERSUS PLACEBO IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH TREATMENT‐NAÏVE FOLLICULAR LYMPHOMA (PERSPECTIVE). (June 2017) Authors: Rule, S.; Flinn, I.W.; Fowler, N.; Chen, R.; Kwei, L.; Beaupre, D.M.; Chu, A.D.; Gordon, L.I. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 427 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY. (June 2017) Authors: Sharman, J.P.; Brander, D.M.; Mato, A.; Kambhampati, S.; Burke, J.M.; Lansigan, F.; Schreeder, M.T.; Lunin, S.D.; Ghosh, N.; Zweibach, A.; Shtivelband, M.I.; Travis, P.M.; Chandler, J.; Kolibaba, K.S.; Sporteli, P.; Miskin, H.P.; Weiss, M.S.; Flinn, I.W. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL). (12th June 2019) Authors: Tam, C.S.; Quach, H.; Nicol, A.; Badoux, X.; Rose, H.; Prince, H.M.; Leahy, M.F.; Eek, R.; Wickham, N.; Patil, S.S.; Huang, J.; Prathikanti, R.; Wang, L.; Reed, W.; Flinn, I.W. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗